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C.R.G. Quick2 and A.W. Bradbury11University Department of Vascular Surgery, Birmingham Heartlands Hospital, Birmingham, and
2Department of Surgery, Hinchingbrooke Hospital, Huntingdon, UKBackground. The UKMulticentre Aneurysm Screening Study (MASS) showed a 44% reduction in AAA-related mortality
after 4 years and predicted an increased number of deaths prevented in the longer term. We aim to compare the 5 and 13 years
benefit from aneurysm screening in the Huntingdon Aneurysm screening programme.
Methods. Incidence and mortality of ruptured AAA (RAAA) after 5 and 13 years of screening in a population based
aneurysm screening program.
Results. Five years of screening resulted in a reduction in the incidence of RAAA of 49% (95% CI: 3–74%). Nine out of 11
ruptures in the invited group did not survive (mortality 82%; 95% CI: 48–98%) compared to 38 non-survivors from 51
ruptures in the control group (mortality 75%; 95% CI: 60–86%). Five years of screening resulted in an RAAA-related
mortality reduction of 45% (95% CI:K15 to 74%). After 13 years of screening the incidence of RAAAwas reduced by 73%
(95% CI: 58–82%). Twenty-one out of 29 ruptures in the invited group did not survive (mortality 72%; 95% CI: 53–87%)
compared to 64 non-survivors from 82 ruptures in the control group (mortality 78%; 95% CI: 68–86%). Thirteen years
screening resulted in a reduction of mortality from RAAA of 75% (95% CI: 58–84%). The number needed to screen to
prevent one death reduced from 1380 after 5 years to 505 after 13 years. The number of elective AAA operations needed to
prevent one death reduced from 6 after 5 years to 4 after 13 years.
Conclusion. AAA screening becomes increasingly beneficial as screening continues over the longer term. Benefits continue
to increase after screening has ceased.Keywords: Abdominal aortic aneurysm; Screening; Long term benefits.Introduction
Ruptured abdominal aortic aneurysms (RAAAs) are
the cause of 1.7% of all male deaths over the age of 65
in England andWales.1 In 2002, there were 5370 deaths
due to RAAA in the England and Wales.1
The aim of screening for asymptomatic abdomi-
nal aortic aneurysms (AAAs) is to prevent their
rupture. The best evidence for the efficacy of
screening comes from the Multicentre Aneurysm
Screening Study (MASS) which showed a 44%
reduction (95% CI: 23–59%) in AAA-related mor-
tality in the invited group compared with the
control group.2ing author. Teun Wilmink, MD, MPhil, FRCS, Univer-
ent of Vascular Surgery, Research Institute, Birming-
nds Hospital, Lincoln House, Bordesley Green East,
B9 5SS, UK.
: abmw100@doctors.org.uk
0016+ 05 $35.00/0 q 2006 Elsevier Ltd. All rights reserA separate paper from the same study, on the cost
effectiveness of screening, suggested that over a longer
period, cost effectiveness would improve substan-
tially: those in whom death is prevented during the
first 4 years would continue to accumulate additional
life years. More deaths would be prevented after 4
years, whilst the costs of follow-up related to screening
would increase only marginally.3 We have published
the effect of screening on the incidence of ruptured
aneurysms after 5 years.4 A second round of screening
commenced in June 1998 and all men over the age of 55
were re-invited to attend screening for a second time
after an average of 5.5 years in order the investigate the
incidence of new aneurysms. From 1999 onwards only
5% of new subjects were screened for the first time and
enrolled in the screening program. Seventy-one new
aneurysms (2.0%) were found in 3606 patients with an
initially normal aorta who were re-screened. The
incidence of new aneurysms was 3.5 per 1000 personEur J Vasc Endovasc Surg 32, 16–20 (2006)
doi:10.1016/j.ejvs.2005.12.016, available online at http://www.sciencedirect.com onved.
Multicentre Aneurysm Screening Study Group 17years (95% CI: 2.8–4.4).5 This paper addresses the
question of whether the benefit ratio of screening
increases over time and whether it continues to
increase after screening has ceased. The Huntingdon
Aneurysm screening project stopped screening in
September 2001. We collected data about elective
AAA surgery and ruptured AAA till 31 December of
2003 in order to compare the reduction in the incidence
of ruptured aneurysms as an observed effect of
screening after 5 years and after 13 years.Methods
Study population: The Huntingdon aneurysm screening
program started in November 1991. The methods of
recruitment and screening have been previously
described.6 In brief, all men in the district over the
age of 50 who were registered with a GP were invited
for screening. Patients were excluded if deemed not to
be suitable for elective open aneurysm repair. These
exclusion criteria included end-stage cardiac or
respiratory disease, end-stage carcinoma, and senile
or pre-senile dementia. Less than 2% of eligible men
were excluded. Screening was organised in one GP
practice at a time and the subjects were invited for
screening through their GP. The study period
extended from 1st January 1991 to 31st December 2003.
Screening: Screening was performed with ultrasono-
graphy, the methods of which have previously been
described.7Tracing ruptured abdominal aortic aneurysms
The Huntingdon aneurysm screening project stopped
screening in September 2001. However, we collected
data about elective AAA surgery and ruptured AAA
till the end of 2003. A thorough attempt was made to
trace all aneurysm ruptures occurring in the District
during the study period, independent of whether the
patient reached hospital or not. We were fortunate in
that Hinchingbrooke Hospital is the only general
hospital in the district and thus all patients with a
RAAA would have been received in Hinchingbrooke
Hospital. All operations performed in the hospital
from 1990 have been logged into the hospital’s
computer system. In addition, from 1988, all Coroners’
post-mortems performed on sudden unexpected
deaths in the community have been performed at
Hinchingbrooke Hospital.
In 1999, a vascular rota with neighbouring Adden-
brooke’s hospital in Cambridge was set up. Most
patients with a RAAA were operated in Cambridge.However, all these patients are initially referred to the
Accident and Emergency Department of Hinching-
brooke Hospital as the ambulance crew is obliged to
take the patients to the nearest hospital. A combination
of methods was used to trace all ruptures occurring in
the district between 1 January 1991 and 31 December
2003: first, patients admitted to hospital with RAAAs
were identified using the hospital computer system,
ICU admission records and operation theatre registers;
second, accident and emergency department records
were examined to identify patients with RAAAs who
were assessed within the department and sub-
sequently died or were transferred to another hospital.
Lastly, we scrutinised all post-mortem reports on
patients during the study period to find any sudden
deaths caused by RAAA outside the hospital.
The identities of all men who presented with a
RAAAduring the study period werematchedwith the
database of the Huntingdon Aneurysm Screening
programme to establish whether an invitation for
screening had been sent.Calculation of follow up
The identities of all men invited for screening and their
appointment dates were retrieved from the database of
the Huntingdon Aneurysm Screening Project. The
start of the study period was set at 1 January 1991 and
the end at 31 December 1996 for the estimation of short
term results and 31 December 2003 for the estimation
of the long term results. All men invited for screening
were assigned to the ‘invited’ group from the date of
their first screening appointment. A ruptured AAA
was allocated to the ‘not-invited’ group if it occurred
before the date of the first appointment and to the
‘invited’ group if it occurred after the date of the first
screening appointment.
Population estimates of all men over the age of 50 in
Huntingdon district for the years 1991–2003 were
obtained from the Office of National Statistics. The
total person-years follow-up of the entire male popu-
lation over 50 in Huntingdon district during the study
period, i.e. both the ‘invited’ and ‘not-invited’ groups,
was calculated by summing the population estimates
between 1991 and 1996 and 1991 and 2003, respectively.
The person-years follow-up in the invited group was
calculatedbymultiplying thenumberof subjects invited
in each year by their average follow up time (Table 1).
Subjects lost to followupwere traced via the database of
the Cambridge and Huntingdon Health Authority.
Those lost to follow up were censored from their date
of removal from the registers. The person years follow-
up in the not-invited group is calculated by subtractingEur J Vasc Endovasc Surg Vol 32, July 2006
Table 1. Estimates of the male population over the age of 50 in
Huntingdon district and number of subjects invited and screened
for the first time in the screening programme in each year
Year Male popu-
lationO50
Invited Screened
1991 15,876 195 126
1992 16,261 2881 2027
1993 16,501 2441 1852
1994 16,790 1978 1453
1995 17,120 2115 1584
1996 20,000 3822 2879
1997 21,000 2106 1401
1998 21,800 2126 1606
1999 22,200 78 56
2000 23,200 480 402
2001 23,700 326 248
2002 24,200 0 0
2003 24,800 0 0
Total 263,448 18,548 13,634
T. Wilmink et al.18the total follow-up in the invited population from the
total person-years follow-up of the entire male popu-
lation over the age of 50 inHuntingdon District over the
study period. The same procedure was followed for the
entire studyperiod from1991 till 31December 2003. The
follow-up of the group invited for screening for the
entire studyperiod up to 2003was 148,591 person years,
after censoring for loss of follow up (Table 1). The total
person-years at risk of the study populationwas 263,448
person-years. The follow up in the group not invited for
screening was calculated as 243,448K148,506Z114,942
person-years.
Incidence rates and confidence intervals of rup-
tured AAA were calculated based on the Poisson
likelihood, using STATA 8.1 for Windows.8Table 2. Comparison of the effect of screening on the incidence and
mortality of RAAA in the first 5 years of screening and over the
whole study period
1991–1996 1991–2003
Male population at risk (py) 100,011 263,448
Number invited 13,147 18,548
Number screened 9657 13,634
Follow up in
screenedpopulation (py)
29,713 148,506
Total number of RAAA in men 62 111
RAAA in invited group 11 29
RAAA in not-invited group 51 82
Incidence RAAA invited
group
2.7 (1.1–5.6) 2.0 (1.3–2.8)
Incidence RAAA not-invited
group
7.3 (5.5–9.4) 7.1 (5.7–8.9)
Incidence rate ratio 0.51 (0.26–0.97) 0.27 (0.18–0.42)
Mortality RAAA invited
group
3.0 (1.4–5.4) 1.4 (0.9–2.2)
Mortality RAAA not-invited
group
5.4 (3.9–7.3) 5.6 (4.3–7.1)
Mortality rate ratio 0.55 (0.26–1.15) 0.25 (0.16–0.42)Results
Between 19 November 1991 and 31 December 2003,
18385 men over the age of 50 in Huntingdon district
were invited for screening. From 1999 till September
2001 only 884 (4.8%) new entries were enrolled in the
screening programme (Table 1). The Huntingdon
aneurysm screening project stopped screening in
September 2001. In total 623 small AAA (O3 cm) and
71 large AAA (O5 cm) were found. No large AAAwas
found in subjects with an aortic diameter smaller than
3 cm on first screen. In total 117 elective aneurysm
repairs were performed on screened patients and 12
emergency operations were performed on screened
patients. All these operations were open repairs. In
total 30 ruptures occurred in men who had been
invited for screening and 18 ruptures occurred in
screened subjects. All the screened ‘ruptures’ had
abnormal aortic diameters (O30 mm) on their initial
ultrasound scan. A detailed analysis of all rupturedEur J Vasc Endovasc Surg Vol 32, July 2006AAA which occurred in patients who were screened
till 2000 has been published elsewhere.9
Our comparison between the short term benefits
(5 years) and the long term benefits (13 years) shows
that the reduction in the incidence and mortality of
ruptured AAA continued to increase over time. The
reduction in incidence of ruptured aneurysms in the
group invited for screening was 49% (95% CI: 3–74%)
after the first 5 years of the screening programme,
compared to 73% (95% CI: 58–82%) after 13 years of
screening. In the first 5 years of screening, nine out of
11 ruptures in the invited group did not survive
(mortality 82%; 95% CI: 48–98%) compared to 38 non-
survivors from 51 ruptures in the control group
(mortality 75%; 95% CI: 60–86%) We reported an
estimated reduction in the mortality rate of ruptured
aneurysms in the group invited for screening
compared to the control group, of 45% (95% CI: K15
to 74%).4 Over the entire study period of 13 years, 21
out of 29 ruptures that occurred in the invited group
did not survive (mortality 72%; 95% CI: 53–87%),
compared to 64 deaths from 82 ruptures in the control
group (mortality 78%; 95% CI: 68–86%). Thus after 13
years of screening, we estimate a reduction in the
mortality rate for ruptured aneurysms of 75% (95% CI:
58–85%) (Table 2).
Only men were screened in Huntingdon. Therefore,
the benefit of screening can also be illustrated by a
change in the proportion of male to female ruptures
during the study period. In the first 5 years of the
screening programme a total of 78 ruptures was found:
62 males (79%) and 16 females (21%). In the last 3 years
of the screening programme and after screening had
ceased, 29 ruptured aneurysms were found: 18 in men
(62%) and 11 in women (38%).
Table 3. Comparison of the effect of screening on the numbers
needed to screen and the numbers needed to treat in the first 5
years of screening and over the whole study period
1991–1996 1991–2003
Deaths observed in screening group 9 21
Deaths expected in screening group 18 52
Elective deaths in screened patients 2 4
Deaths prevented 7 27
Operations on screened patients 40 117
Number of men screened 9657 13,634
Number needed to treat 6 4
Number needed to screen 1380 505
Multicentre Aneurysm Screening Study Group 19That the absolute benefits of screening also
increases over time is illustrated by a reduction in
both the numbers needed to screen and the number of
elective aneurysm repairs on screened patients needed
to prevent one death (Table 3).Discussion
Our comparison of the short-term and medium-term
effect of screening for asymptomatic AAA on the
incidence and mortality of RAAA shows a clear
increase in the reduction of RAAA after the longer
follow up period. As expected, the benefits of screen-
ing continued to increase after screening was stopped.
Our study period continued only for 2 years longer
than the screening program. We would expect that the
benefits will continue to increase for some time longer
after screening has been stopped. This, however, relies
firstly on the continuation of a small aneurysm
surveillance programme as no ruptures occurred in
patients with a normal aortic diameter on first screen.
Secondly, we would need to restart screening in 7
years time when the men who were younger than 50 at
the start of the screening program reach the age of 65.
The main limitation of this study is that it is not a
randomised controlled trial. However, we believe that
our study is unbiased without strict randomisation
because, of the stepped wedge design.4,10 Each person
was in the control group before the date of the first
screening appointment and contributed to the follow
up of the control (‘not-invited’) population before any
appointment had been given. Each subject entered the
‘invited’ group and contributed to the follow-up of the
‘invited’ population after the appointment date. So
each subject acted as his own control. We calculated
the incidence of ruptured AAA on an ‘intention to
treat analysis’ on the basis of whether an invitation
had been given, irrespective of whether or not the
subjected attended. A ruptured AAAwas allocated to
the ‘not-invited’ group if it occurred before the date ofthe first appointment and to the ‘invited’ group if it
occurred after the date of the first screening appoint-
ment. It is possible that the population not yet invited
for screening differed from those who had been
invited but this is unlikely as screening was carried
out for one GP practice at a time. There was no
predetermined order in which the GP practices were
asked to participate in the screening programme, nor
was there a predetermined order for invitation of
subjects within practices as they were invited in
alphabetical order according to surname. Therefore,
the time at which any given subject entered the
‘invited’ group can be considered to have been
allocated at random and could not have been
predicted, thus minimising bias.4 Volunteer bias was
minimised by employing an ‘intention to treat
analysis’ on the basis of whether an invitation had
been given, rather than on whether screening had
taken place.
Our estimates of the effect of screening on the
incidence and mortality of RAAA correlate very well
with other studies. Our estimate of a reduction in
cause specific mortality of 45% after 4 years of
screening corresponds closely with the MASS study.
Our estimates in the reduction of incidence of RAAA is
only slightly lower than the estimates of a randomised
trial of screening fromChichester which showed a 55%
reduction in the incidence of rupture after 5 years.11
Our longer term estimates also correspond well with
other studies: a study from Gloucester, using a
different screening method and a different study
design, found a reduction in the incidence of RAAA
of 66% after 14 years of screening.12 A recent study
from Denmark, which did not include deaths outside
the hospital, found a 74% reduction the incidence of
RAAA and a 68% reduction in cause specific
mortality.13 We believe, therefore, that our estimates
of the longer term benefits of screening are accurate
and unbiased.Conclusion
Screening for AAA becomes increasingly beneficial as
screening continues over the longer term. Benefits
even continue to increase after screening has ceased.References
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